Summary

Ten years after the identification of the JAK2V617F mutation in most patients with myeloproliferative neoplasms, the understanding of the pathophysiology and genomic landscape of MPNs has evolved. The enhanced understanding and recognition of the impact of symptomatic burden on risk have led to targeted therapies and new treatment paradigms.